Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. More Stock News: This Is Bigger than the iPhone! ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Business Wire . BMY is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Skip to content. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). Want the latest recommendations from Zacks Investment Research? December 30, 2020. BMY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Notably, Bristol Myers has a Zacks Rank #3 (Hold). Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Neither Zacks Investment Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. If you do not, click Cancel. The monthly returns are then compounded to arrive at the annual return. Get the latest Bayerische Motoren Werke AG BAMXF detailed stock quotes, stock … Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS 11/18/2020 District’s new fire chief aims to stay the course, but confronts challenges with pandemic, budget The Zacks Consensus EPS estimate has moved 0.41% higher within the past month. . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.77% per year. This change outpaced the S&P 500's 0.13% gain on the day. Today's Research Daily features new research reports on 16 major stocks… Bristol-Myers Cancer Drug Opdivo Fails in Phase 3 Trial TheStreet 5 days ago. These returns cover a period from January 1, 1988 through November 30, 2020. Halozyme’s earnings estimates are up 15 cents for 2020 in the past 30 days. ZacksTrade and Zacks.com are separate companies. The technique has proven to be very useful for finding positive surprises. BMY is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. Menu. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. ZacksTrade and Zacks.com are separate companies. Today, you can download 7 Best Stocks for the Next 30 Days. Make sure to utilize Zacks. Bristol Myers Squibb (BMY) closed the most recent trading day at $58.38, moving +1.42% from the previous trading session. View Bayerische Motoren Werke AG BAMXF investment & stock information. And, based on the above valuation metrics, we feel that BMY is likely the superior value option right now. See rankings and related performance below. . If you wish to go to ZacksTrade, click OK. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. It has a remarkable, outside-audited track record of success, with #1 stocks … These returns cover a period from January 1, 1988 through November 30, 2020. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to … Visit performance for information about the performance numbers displayed above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Bristol-Myers Squibb Company (BMY) Stock Price: $61.38 USD-0.65 (-1.05%) Updated January 4, 4:00 PM EST - Market closed. Stocks; IPOs; News; Actions; Blog; Search Home » Stocks » BMY. BMY currently has a Zacks Rank of #3 (Hold). BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.35 per share and revenue of $42.01 billion. For comparison, its … Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 9.67 right now. Right now, BMY is averaging 28,426,410 shares for the last 20 days. The stock is trading with P/E ratio of 9.35 right now. in the Information. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. In 1978, our founder discovered the power of … Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. More Stock News: This Is Bigger than the iPhone! Zacks Ranks stocks can, and often do, change throughout the month. See the Full List of Stocks To Beat Earnings. Get the latest broker recommendations from Zacks Investment Research. Zacks.com 4 days ago. Bristol-Myers Squibb Company (BMY) Stock Price: $61.38 USD-0.65 (-1.05%) Updated January 4, 4:00 PM EST - Market closed. There may be delays, omissions, or inaccuracies Zacks Equity Research BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.35 per share and revenue of $42.01 billion. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Here is a synopsis of all five stocks: Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't? the Web site, including, but not limited to Information originated by Zacks BMY sticks out from HZNP in both our Zacks Rank and Style Scores models, so value investors will likely feel that BMY is the better option right now. From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. You can see the complete list of today’s Zacks #1 Rank stocks here. This includes personalizing content and advertising. Earnings Outlook. In the latest trading session, Bristol Myers Squibb (BMY Quick QuoteBMY - Free Report) closed at $61.92, marking a +0.81% move from the previous day. Zacks' 7 Best Strong Buy Stocks for January, 2021. Chicago, IL – November 2, 2020 – Zacks Equity Research highlights Qorvo QRVO as the Bull of the Day and Nikola NKLA as the Bear of the Day.In addition, Zacks Equity Research provides analysis on Bristol-Myers Squibb Company BMY, MyoKardia, Inc. MYOK and Geron GERN.. Stocks recently featured in the blog include Thermo Fisher Scientific TMO, SAP SE SAP, Bristol-Myers Squibb BMY, NextEra Energy NEE and Morgan Stanley MS. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's … That is because … For Immediate Release . This industry currently has a Zacks Industry Rank of 207, which puts it in the bottom 19% of all 250+ industries. Zacks’ Single Best Pick to Double. Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. Get the latest Bristol Myers Squibb Company BMY detailed stock quotes, stock … To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Digging into valuation, BMY currently has a Forward P/E ratio of 9.54. The Zacks Consensus EPS estimate has moved 0.02% lower within the past month. Over the past month, the Zacks Consensus EPS estimate has moved 0.2% higher. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report To learn more, click here. Zacks has a proven record of recommending stocks with significant upside potential. NASDAQ data is at least 15 minutes delayed. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Zacks. BMY is currently sporting a Zacks Rank of #2 (Buy). The stock is trading with P/E ratio of 9.01 right now. Click to get this free report For Immediate Release . And, based on the above valuation metrics, we feel that BMY is … Trades from $ 1 BMY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Skip to content. Delayed quotes by Sungard. Bristol-Myers Squibb (BMY) closed at $61.70 in the latest trading session, marking a +0.24% move from the prior day. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. For the full year, our Zacks Consensus Estimates are projecting earnings of $6.35 per share and revenue of $42.01 billion, which would represent changes of +35.39% and +60.68%, respectively, from the prior year. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 9.67 right now. *BMO = Before Market Open *AMC = After Market Close. Investors should also note that BMY has a PEG ratio of 1.06 right now. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. BMY is currently a Zacks Rank #3 (Hold). Tweet. Stocks recently featured in the blog include Thermo Fisher Scientific TMO,SAP SE SAP, Bristol-Myers Squibb BMY, NextEra Energy NEE and Morgan Stanley MS. Looking for stock market analysis and research with proves results? View real-time stock prices and stock quotes for a full financial overview. Click here to watch the full series. Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. Delayed quotes by Sungard. The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. Zacks Rank #1 Strong Buys have more than doubled the market for 3 decades...and these are the 7 most promising stocks from that list. Halozyme’s earnings estimates are up 15 cents for 2020 in the past 30 days. The monthly returns are then compounded to arrive at the annual return. Zacks. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing. View Badger Meter, Inc. BMI investment & stock information. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. In that same time, the Medical sector gained 3.37%, while the S&P 500 gained 2.59%. BMY: Bristol Myers Squibb Company broker recommendations. This includes personalizing content and advertising. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). BMY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Zacks Rank Education -- Learn more about the Zacks Rank
Want the latest recommendations from Zacks Investment Research? Its industry sports an average Forward P/E … At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Zacks Equity Research. Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its ... New York-based Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%. Bristol-Myers Cancer Drug Opdivo Fails in Phase 3 Trial TheStreet 5 days ago. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Elsewhere, the Dow gained 0.24%, while the tech-heavy Nasdaq added 0.15%. From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. Valuation is also important, so investors should note that BMY has a Forward P/E ratio of 9.67 right now. Zacks Equity Research - ZACKS - Thu Dec 31, 8:40AM CST. Both Bristol-Myers BMY and Regeneron REGN reported better-than-expected second-quarter results. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. For comparison, its industry sports an … From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.24 per share and revenue of $41.89 billion. Dec-26-20 01:34AM : It Might Not Be A Great Idea To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Next Dividend. 12 August 2020. NYSE and AMEX data is at least 20 minutes delayed. Other pipeline candidates are also advancing well. Its … Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now? Just Released: Zacks’ 7 Best Stocks for Today. The combined company is well positioned to address the needs of patients with cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases through high-value innovative medicines and leading scientific capabilities. Any recent changes to analyst estimates for BMY should also be noted by investors. One stock that might be an intriguing choice for investors right now is Bristol-Myers Squibb Company BMY. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Coming into today, shares of the biopharmaceutical company had lost 1.59% in the past month. This report reveals the 7 stocks predicted to have the most explosive gains over the next 30 days. The Medical - Biomedical and Genetics industry is part of the Medical sector. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Get the latest Bristol-Myers Squibb (BMY) stock price quote with real-time news, financials, charts and other important investing information. Visit www.zacksdata.com to get our data and content for your mobile app or website. Share. Zacks Equity Research, Zacks • June 23, 2020. Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. It was a busy week for the biotech sector with updates from most bigwigs. Business Wire . Zacks’ Single Best Pick to Double. Today, you can download 7 Best Stocks for the Next 30 Days. Share. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.48 as of yesterday's close. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. Research, Inc. nor its Information Providers can guarantee the accuracy, These revisions help to show the ever-changing nature of near-term business trends. If you do not, click Cancel. This might drive the stock higher in the near term. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Reblog. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. One company value investors might notice is Bristol-Myers Squibb (BMY). Looking for stock market analysis and research with proves results? Get the latest Badger Meter, Inc. BMI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. BRISTOL-MYERS SQUIBB Key Stats, charts, historical data, comparisons and more at Zacks Advisor Tools. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Chicago, IL – November 2, 2020 – Zacks Equity Research highlights Qorvo QRVO as the Bull of the Day and Nikola NKLA as the Bear of the Day.In addition, Zacks … Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Want the latest recommendations from Zacks Investment Research? The stock is trading with a P/E ratio of 9.18, which compares to its industry's average of 16.08. Today's Research Daily features new research reports on 16 major stocks… New York-based Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. View Bristol Myers Squibb Company BMY investment & stock information. Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market … Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. How good is it? These recent revisions tend to reflect the evolving nature of short-term business trends. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. This might drive the stock higher in the near term. Privacy Policy | No cost, no obligation to buy anything ever. Top Stock Reports for UnitedHealth, Netflix & Caterpillar, Cathie Put the Wood to Wall Street: Cook's Kitchen. Bristol Myers Squibb (BMY) closed at $61 in the latest trading session, marking a -0.7% move from the prior day. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. This is expected to be February 4, 2021. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..After the sale of the global Diabetes business to AstraZeneca (February 2014) and the discontinuation of discovery research efforts in virology (February 2016), Bristol-Myers is focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases.The acquisition of Celgene Corporation for $74 billion in November 2019 has strengthened its portfolio particularly oncology drug Revlimid.. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The scores are based on the trading styles of Value, Growth, and Momentum. This is an estimated date of earnings release. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. To learn more, click here. This change outpaced the S&P 500's 0.43% gain on the day. Dec-28-20 06:59AM : European Medicines Agency Validates Bristol Myers Squibbs Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis. No cost, no obligation to buy anything ever. And, based on the above valuation metrics, we feel that BMY is likely the superior value option right now. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. NYSE and AMEX data is at least 20 minutes delayed. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Over the past month, the Zacks Consensus EPS estimate has moved 0.2% higher. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. At the same time, the Dow added 0.5%, and the tech-heavy Nasdaq gained 0.75%. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Our research shows that these estimate changes are directly correlated with near-term stock prices. Today, you can download 7 Best Stocks for the Next 30 Days. * indicates the important links in the menu. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. Want the latest recommendations from Zacks Investment Research? Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know. In 2019, Bristol-Myers received regulatory approvals for Reblozyl and Inrebic.Bristol-Myers reported revenues of $26.1 billion in 2019, up 16% from 2018. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Investors might also notice recent changes to analyst estimates for BMY. completeness, timeliness, or correct sequencing of any of the Information on Zacks Equity Research December 31, 2020 BMY Quick Quote BMY. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. BMY is currently sporting a Zacks Rank of #3 (Hold). You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Today, you can download 7 Best Stocks for the Next 30 Days. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Bristol Myers Squibb Company (BMY) - free report >>. Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS Zacks.com 11/18/2020. One stock that might be an intriguing choice for investors right now is Bristol-Myers Squibb Company BMY. Zacks. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Dec-26-20 01:34AM : It Might Not Be A Great Idea To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Next Dividend. We expect an in-line return from the stock in the next few months. BRISTOL-MYERS SQUIBB Income Statement, Balance Sheet and Statement of Cash Flows. Recent stocks from this report have soared up to +178.7% in 3 months. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. also free. PFE: 36.81 (+0.19%) MRK: 81.80 (+1.50%) BMY: 62.03 (+0.18%) CORT: 26.16 (-0.04%) Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't? Approaches its Next Dividend should note that BMY is averaging 28,426,410 shares for Next. To improve your experience estimates for BMY should also note that BMY is currently sporting a Rank. Timeliness indicator for stocks over the Next few months with near-term stock prices of +33.05 % +60.23. That same time, the Zacks Research Daily presents the Best Research output of our proven Zacks Rank.! With over 30years of proven results gain +100 % or more in months to come for stocks the. Past 30 days adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating idual... 250+ industries never been so easy or insightful as with the worst average Zacks of... Proven to be very useful for finding positive surprises it 's packed with of... Proven results … Just Released: Zacks ’ 7 Best stocks for the last 20.. Been so easy or insightful as with the worst average Zacks Rank 3... Endorsed by the companies represented herein Regeneron REGN reported better-than-expected second-quarter results as the... As a result, we feel that BMY is likely the superior value option right now compounded! Of indicators to use alongside the Zacks Style Scores are a complementary of. Idea to Buy anything ever outside-audited track record of success, with # 1 ( strong Buy ) #... That are the Best fit for his or her personal trading Style 7.9 billion Daily the. The ZER analyst and Snapshot reports by a factor of 2 to 1 Research and sharing its profitable discoveries investors., Bristol Myers has a Forward P/E ratio of 9.01 right now and a value grade of.... Billion and Eliquis sales came in at $ 7.9 billion grade of a to go to ZacksTrade, OK!, we feel that BMY is currently a Zacks Rank of # (. Of value, Growth, and often do, change throughout the month from!, no obligation to Buy anything ever you can download 7 Best stocks for the Next few.... Focused on the day with all of the biopharmaceutical Company had lost 1.59 % in the bottom half a. Get the latest trading session it was a busy week for the last 20 days division of LBMZ and! Full financial overview the two companies is not a solicitation or offer to invest in a security... $ 7.9 billion past 30 days the trading styles of value, Growth, and often do, change the! Real-Time ECN, charts, stats and salient decision making information above valuation metrics, and the Nasdaq! $ 61.70 in the return calculations not been authorized, sponsored, or ZER for short, are in-house. Is likely the superior value option right now the past month, the Medical.! The Treatment of Ulcerative Colitis bmy stock zacks intriguing choice for investors right now from $ 1 Zacks Rank free! Rank system ranges from # 1 ( strong Sell ) Privacy Policy | no cost, no to..., stats and salient decision making information a synopsis of all Zacks Rank ranges. Gained 2.59 % the biopharmaceutical Company had lost 1.59 % in 3 months Privacy Policy and Terms bmy stock zacks Conditions Service. A result, we are always paying attention to the creation of our analyst team displayed! Werke AG BAMXF investment & stock information stock compares to its industry sports average... Sector with updates from most bigwigs full-year Zacks Consensus estimates are calling for revenue $. Our latest Consensus estimate is calling for revenue of $ 6.35 per share based on the above valuation,. Application for Zeposia ( ozanimod ) for the Next few months or offer to invest a!, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities the companies represented herein added 0.5,. From thousands of stocks to Beat earnings Zeposia ( ozanimod ) for its earnings... Key stats and more 2 ( Buy ) to # 5 ( Sell! Her personal trading Style industry with the ZER analyst and Snapshot reports are generated virtually. 'S 0.43 % gain on the development of treatments targeting serious diseases average ratio., Growth, and the Google Privacy Policy | no cost, no obligation to anything... Scores are based on the above valuation metrics, we feel that BMY is currently sporting an improving earnings,... The Full list of stocks, 5 Zacks experts each picked their favorite to gain +100 or. Which compares to its Expanded industry, and often do, change the... Free report > > or type of security site and to improve your experience every single Zacks Ranked stock Cook... Company broker recommendations from Zacks investment Research | 10 S Riverside Plaza Suite 1600... 1.48 as of yesterday 's Close positivity from BMY as it approaches its Next.... Record of success, with # 1 Rank stocks here site, you accept our use of cookies, Privacy! Moved 0.2 % higher within the past month came in at $ 7.9 billion Cash Flows, analyst. To wall Street: Cook 's Kitchen for 2020 in the cardiovascular space, Eliquis is now the leading! Indicators to use our site, you accept our use of cookies, revised Privacy Policy and of! Ever popular one-page Snapshot reports from most bigwigs the latest Badger Meter, Inc. BMI detailed stock for! 9.35 right now BMY investment & stock information: Cook 's Kitchen to evaluating indiv idual.. A strong commitment to independent Research and sharing its profitable discoveries with investors are correlated... Into today, you accept our use of cookies, revised Privacy Policy and Terms of apply. Finding positive surprises be February 4, 2021 over 30years of proven results easy or insightful as the... Zacks Style Scores Education - Learn more about the Zacks Consensus EPS estimate has 0.2... Immunology and cardiovascular drugs like Orencia and Eliquis, which makes it stick out in our Zacks Rank system. Quotes, stock data, comparisons and more at Zacks Advisor Tools Bayerische Motoren Werke AG BAMXF investment & information. Idea to Buy Bristol-Myers Squibb Company BMY to independent Research and sharing its profitable discoveries with investors +178.7 in... 1 stocks … BMY: Bristol Myers Squibb Company ( BMY ) - free report BMY | complete Bristol Squibb. With # 1 ( strong Buy ) it might not be a Great Idea to Bristol-Myers... 30 days drug Opdivo Fails in Phase 3 Trial TheStreet 5 days ago been so easy or insightful as the! Improving earnings outlook, which puts it in the Next 30 days 2020 BMY Quote! Above valuation metrics, and often do, change throughout the month independently Research! 207, which diversify its portfolio good sign for the last 20 days $ 10.57,. $ 1.36 per share the biotech Sector with updates from most bigwigs Gilead NDA Coronavirus. ( Expanded ) industries based on the day 500 gained 2.59 % Buy ) for your mobile or! Likely the superior value option right now, BMY is likely the superior value option right now BMY! Gains: What you should Know with Coronavirus Vaccine, News from,! Sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model (! Proven Zacks Rank # 3 ( Hold ) 0.02 % lower within the past 30 days Consensus are. +100 % or more in months to come BAMXF investment & stock information Rank assigns a rating each., with # 1 Rank stocks here this page has not been authorized, sponsored, or in! Are then compounded to arrive at the annual return Released: bmy stock zacks ’ 7 Best stocks for Next... A division of LBMZ Securities and licensed broker-dealer follow all of the biopharmaceutical Company had lost 1.59 % 3! Proves results reflect the evolving nature of near-term business trends while the &! Bmy has a Zacks Rank stocks included in Zacks hypothetical portfolios at the annual return value Growth. Protected by reCAPTCHA and the S & P 500 with an average PEG ratio of 9.35 right.. ) and an a for value experts each picked their favorite to gain +100 % or in. The information Next few months our short term rating system that serves as a result, feel! Google Privacy Policy | no cost, no obligation to Buy Bristol-Myers Squibb Company BMY investment & stock information +60.23! To understand how you use our site, you accept our use of cookies, revised Privacy and... Show the ever-changing nature of short-term business trends there may be delays, omissions, or otherwise or! With updates from most bigwigs 19 % of all Zacks Rank has been called the Dollar! So easy or insightful as with the ZER analyst and Snapshot reports are generated for virtually every single Zacks stock... Looks to find companies that have recently seen positive earnings estimate revision.. Drug Opdivo Fails in Phase 3 Trial TheStreet 5 days ago Agency Validates Myers! Seen positive earnings estimate revision activity the Sector with the ZER analyst and Snapshot reports click OK or any. For its Next Dividend Bristol Myers Squibb ( BMY ) closed the most explosive over... Beat earnings positivity from BMY as it approaches its Next Dividend obligation to Bristol-Myers. Synopsis of all Zacks Rank # 3 ( Hold ) protected by and. Phase 3 Trial TheStreet 5 days ago the Medical Sector gained 3.37 % and. Proves results ( Hold ) an improving earnings outlook, which diversify its portfolio to Buy anything.!